Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress extends federal funding temporarily

This article was originally published in The Tan Sheet

Executive Summary

Congress Sept. 30 passes a continuing resolution maintaining funding for FDA and other federal agencies at fiscal 2010 levels. The CR expires Dec. 3. If Republicans win a majority in the midterm elections in November, during the subsequent lame-duck session they might force passage of another CR that would the allow the party to set fiscal 2011 spending levels after the 112th Congress begins in January

You may also be interested in...



FDA Strategic Documents Outline Regulatory Science Priorities

Improving regulatory tools and scientific know-how are among FDA's top priorities over the next five years, according to a draft strategic report

2022 Korean VC Financings Led By Mid-Stage Bioventures

Amid a generally harsh environment, venture capital investors in South Korea appeared to take a more selective approach in 2022, with more established and financially stable domestic bioventures the biggest beneficiaries.

New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need

Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel